Corcept Therapeutics Inc/ US2183521028 /
2024-06-03 10:00:00 PM | Chg. +1.1300 | Volume | Bid1:52:30 AM | Ask1:52:30 AM | High | Low |
---|---|---|---|---|---|---|
31.3000USD | +3.75% | 1.11 mill. Turnover: 23.98 mill. |
28.0000Bid Size: 100 | 33.0000Ask Size: 100 | 32.2400 | 29.8800 |
GlobeNewswire
06-03
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Re...
GlobeNewswire
05-28
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients Wi...
GlobeNewswire
05-01
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
GlobeNewswire
04-24
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host ...
GlobeNewswire
04-22
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patient...
GlobeNewswire
04-15
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis ...
GlobeNewswire
04-08
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Plati...
GlobeNewswire
04-01
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cush...
GlobeNewswire
03-06
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
GlobeNewswire
02-15
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provi...
GlobeNewswire
02-15
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
GlobeNewswire
02-08
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corpor...
GlobeNewswire
02-08
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
GlobeNewswire
01-08
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
GlobeNewswire
2023-12-04
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
GlobeNewswire
2023-11-01
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
GlobeNewswire
2023-10-26
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
GlobeNewswire
2023-10-25
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host ...